Boston Scientific Corp.’s Watchman, designed to help prevent strokes in patients with an erratic heartbeat, may be a tougher sell for U.S. regulators after a study failed to confirm the device’s benefit.
Abbott Laboratories’ experimental hepatitis C treatment cured almost half of patients who couldn’t eliminate the virus with therapies now on the market, according to a study that boosted the company’s shares.
Medtronic Inc. ghost-wrote sections of medical papers and paid physician authors hundreds of millions of dollars in “consulting fees” to promote its bone- growth product Infuse, a U.S. Senate investigation found.
St. Jude Medical Inc.’s device to plug openings in the heart after a stroke failed to definitively prevent repeat incidents in patients under age 60 compared with non-surgical drug treatment, two studies found.
Johnson & Johnson ’s antipsychotic medicine Risperdal Consta, its third-best-selling drug, fared no better than less expensive treatments at keeping schizophrenia patients out of the hospital, U.S. researchers said.
Johnson & Johnson Chief Executive Officer William Weldon said he has “no plans right now” to retire and is focused on fixing manufacturing problems that led the company to recall more than 40 consumer brands last year.